



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Wyost

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
WS/2772	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.z - Change in control of the AS - Other variation	07/11/2024	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/11/2024		Labelling and PL	
II/0002/G	This was an application for a group of variations. B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	31/10/2024	n/a		
IB/0001	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	07/10/2024	n/a		